“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande, who departed a16z’s roughly $4 billion biotech practice, launched the smaller AI‑native fund VZVC. He argues that biology is shifting from a discovery discipline to an engineering one, that clinical trials remain prohibitively expensive, and that open, shared datasets—not proprietary ones—are essential for AI to truly transform medicine.

Summary written by Kernelia from the original article by TechCrunch AI. The story and its rights belong to its author.